

---

Advanced Certificate in Biopharmaceutical Packaging

## **Risk Management in Biopharmaceutical Packaging.**

---

### **\*\*Accelerated aging\*\***

Accelerated aging is a testing method used to predict the shelf life and stability of biopharmaceutical products and packaging. It involves exposing the product and packaging to elevated temperatures, humidity, and other environmental conditions to speed up chemical reactions and degradation processes. This allows manufacturers to estimate how the product will degrade over time and ensure that it remains safe and effective throughout its intended shelf life.

### **\*\*Adhesion\*\***

Adhesion refers to the force that causes two surfaces to stick together. In biopharmaceutical packaging, adhesion is important for ensuring that labels, stoppers, and other components remain securely attached to the packaging throughout transportation, storage, and use. Adhesion can be affected by a variety of factors, including surface energy, roughness, and contamination.

### **\*\*Aggregation\*\***

Aggregation is the clumping together of particles or molecules in a solution. In biopharmaceutical packaging, aggregation can occur when proteins or other biologic drugs come into contact with each other, leading to the formation of larger particles or clumps. This can affect the safety, efficacy, and stability of the drug, and may require additional testing and quality control measures to ensure that the product remains within acceptable specifications.

### **\*\*Barrier properties\*\***

Barrier properties refer to the ability of a packaging material to prevent the passage of gases, liquids, and other substances. In biopharmaceutical packaging, barrier properties are critical for maintaining the sterility, stability, and efficacy of the product. Common barrier properties include moisture barrier, oxygen barrier, and light barrier, which can be achieved through the use of coatings, laminates, and other packaging technologies.

### **\*\*Biocompatibility\*\***

Biocompatibility refers to the ability of a material to interact safely and effectively with living tissue and biological systems. In biopharmaceutical packaging, biocompatibility is important for ensuring that the packaging materials do not cause adverse reactions or negatively impact the safety or efficacy of the drug.

---

Biocompatibility testing involves evaluating the potential effects of the packaging materials on cells, tissues, and organs, and may include in vitro and in vivo studies.

**\*\*Blister packaging\*\***

Blister packaging is a type of packaging used for solid dosage forms such as tablets, capsules, and lozenges. It consists of a formed cavity or pocket made of plastic or aluminum, which is then sealed to a backing card or tray. Blister packaging provides several advantages, including tamper evidence, child resistance, and ease of use. It also allows for individual dosing and can help to maintain product stability and shelf life.

**\*\*Container closure integrity (CCI)\*\***

Container closure integrity (CCI) refers to the ability of a package to maintain its seal and prevent the ingress or egress of substances such as air, moisture, and microorganisms. In biopharmaceutical packaging, CCI is critical for ensuring the sterility, stability, and efficacy of the product. CCI testing involves evaluating the seal strength, leak rate, and other properties of the package, and may include non-destructive and destructive testing methods.

**\*\*Drug-device combination products\*\***

Drug-device combination products are medical devices that contain a drug or biologic component. In biopharmaceutical packaging, drug-device combination products present unique challenges related to the packaging and delivery of the drug and device components. These challenges may include compatibility issues, stability concerns, and regulatory requirements. Proper packaging design and testing are essential for ensuring the safety, efficacy, and quality of drug-device combination products.

**\*\*Extractables and leachables\*\***

Extractables and leachables are substances that can migrate from packaging materials into the drug product. Extractables are substances that can be extracted from the packaging material under laboratory conditions, while leachables are substances that actually migrate into the drug product during normal use. Extractables and leachables can affect the safety, efficacy, and stability of the drug, and may require additional testing and quality control measures to ensure that the product remains within acceptable specifications.

**\*\*Glass packaging\*\***

Glass packaging is a common type of packaging used for biopharmaceutical products. Glass is inert, impermeable, and transparent, making it an ideal choice for maintaining product stability, sterility, and visibility. However, glass packaging can be prone to breakage, delamination, and other defects, which can affect product safety and quality. Proper inspection, cleaning, and handling are essential for ensuring the integrity and performance of glass packaging.

**\*\*High-density polyethylene (HDPE)\*\***

High-density polyethylene (HDPE) is a type of plastic commonly used in biopharmaceutical packaging. HDPE is lightweight, durable, and chemically resistant, making it an ideal choice for a variety of applications. HDPE can be formed into bottles, containers, and other shapes, and can be sterilized using a variety of methods. HDPE is also recyclable, making it an environmentally friendly choice for biopharmaceutical packaging.

**\*\*Low-density polyethylene (LDPE)\*\***

Low-density polyethylene (LDPE) is a type of plastic commonly used in biopharmaceutical packaging. LDPE is flexible, transparent, and chemically resistant, making it an ideal choice for a variety of applications. LDPE can be formed into bags, films, and other shapes, and can be sterilized using a variety of methods. LDPE is also recyclable, making it an environmentally friendly choice for biopharmaceutical packaging.

**\*\*Moisture barrier\*\***

Moisture barrier refers to the ability of a packaging material to prevent the ingress or egress of moisture. In biopharmaceutical packaging, moisture barrier is critical for maintaining the stability and efficacy of the product. Moisture barrier can be achieved through the use of coatings, laminates, and other packaging technologies, and may be specified in terms of water vapor transmission rate (WVTR) or moisture vapor transmission rate (MVTR).

**\*\*Oxygen barrier\*\***

Oxygen barrier refers to the ability of a packaging material to prevent the ingress or egress of oxygen. In biopharmaceutical packaging, oxygen barrier is critical for maintaining the stability and efficacy of the product. Oxygen barrier can be achieved through the use of coatings, laminates, and other packaging technologies, and may be specified in terms of oxygen transmission rate (OTR).

**\*\*Particulate matter\*\***

Particulate matter refers to small particles or fragments that can contaminate biopharmaceutical products and packaging. Particulate matter can come from a variety of sources, including the product itself, the packaging materials, the environment, and human handling. Particulate matter can affect the safety, efficacy, and stability of the product, and may require additional testing and quality control measures to ensure that the product remains within acceptable specifications.

**\*\*Plastic packaging\*\***

Plastic packaging is a common type of packaging used for biopharmaceutical products. Plastics are lightweight, durable, and chemically resistant, making them an ideal choice for a variety of applications.

---

Plastics can be formed into bottles, containers, bags, films, and other shapes, and can be sterilized using a variety of methods. Plastics are also recyclable, making them an environmentally friendly choice for biopharmaceutical packaging.

**\*\*Quality by design (QbD)\*\***

Quality by design (QbD) is a systematic approach to product development that emphasizes the importance of understanding and controlling the critical quality attributes (CQAs) of the product and the process. In biopharmaceutical packaging, QbD involves identifying the CQAs of the packaging materials and the packaging process, and designing the process to ensure that the CQAs are consistently met. QbD can help to improve product quality, reduce manufacturing costs, and facilitate regulatory compliance.

**\*\*Rigid packaging\*\***

Rigid packaging is a type of packaging used for biopharmaceutical products that provides structural support and protection. Rigid packaging can be made of glass, plastic, or metal, and can be formed into bottles, containers, trays, and other shapes. Rigid packaging provides several advantages, including tamper evidence, child resistance, and ease of use. It also allows for individual dosing and can help to maintain product stability and shelf life.

**\*\*Sterilization\*\***

Sterilization is a process used to eliminate or inactivate microorganisms from biopharmaceutical products and packaging. Sterilization is critical for ensuring the safety and efficacy of the product, and may be achieved using a variety of methods, including heat, radiation, chemicals, and filtration. Proper sterilization validation and monitoring are essential for ensuring the effectiveness and consistency of the sterilization process.

**\*\*Sterility assurance level (SAL)\*\***

Sterility assurance level (SAL) is a